Literature DB >> 26032396

Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Carolina A Rush1, Heather J MacLean1, Mark S Freedman1.   

Abstract

Multiple sclerosis (MS) is a CNS disorder characterized by inflammation, demyelination and neurodegeneration, and is the most common cause of acquired nontraumatic neurological disability in young adults. The course of the disease varies between individuals: some patients accumulate minimal disability over their lives, whereas others experience a rapidly disabling disease course. This latter subset of patients, whose MS is marked by the rampant progression of disability over a short time period, is often referred to as having 'aggressive' MS. Treatment of patients with aggressive MS is challenging, and optimal strategies have yet to be defined. It is important to identify patients who are at risk of aggressive MS as early as possible and implement an effective treatment strategy. Early intervention might protect patients from irreversible damage and disability, and prevent the development of a secondary progressive course, which thus far lacks effective therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26032396     DOI: 10.1038/nrneurol.2015.85

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  112 in total

1.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

2.  High-dose cyclophosphamide in the treatment of multiple sclerosis.

Authors:  Robert Jay Schwartzman; Nicole Simpkins; Guillermo M Alexander; Erin Reichenberger; Kristine Ward; Noah Lindenberg; David Topolsky; Pam Crilley
Journal:  CNS Neurosci Ther       Date:  2009-02-23       Impact factor: 5.243

3.  Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease.

Authors:  M J Hohol; M J Olek; E J Orav; L Stazzone; D A Hafler; S J Khoury; D M Dawson; H L Weiner
Journal:  Mult Scler       Date:  1999-12       Impact factor: 6.312

4.  Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.

Authors:  O A Khan; M Zvartau-Hind; C Caon; M U Din; M Cochran; D Lisak; A C Tselis; J A Kamholz; J Y Garbern; R P Lisak
Journal:  Mult Scler       Date:  2001-06       Impact factor: 6.312

5.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

6.  Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

Authors:  Jason Ramtahal; Anu Jacob; Kumar Das; Mike Boggild
Journal:  J Neurol       Date:  2006-09-21       Impact factor: 4.849

7.  Characterising aggressive multiple sclerosis.

Authors:  Suresh Menon; Afsaneh Shirani; Yinshan Zhao; Joel Oger; Anthony Traboulsee; Mark S Freedman; Helen Tremlett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-06-06       Impact factor: 10.154

8.  Cognitive presentation of multiple sclerosis: evidence for a cortical variant.

Authors:  M Zarei; S Chandran; A Compston; J Hodges
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

Review 9.  Neuropathology of multiple sclerosis-new concepts.

Authors:  Barbara Kornek; Hans Lassmann
Journal:  Brain Res Bull       Date:  2003-08-15       Impact factor: 4.077

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  26 in total

Review 1.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis.

Authors:  Harold L Atkins; Mark S Freedman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Acute multiple sclerosis lesion pathology does not predict subsequent clinical course-a biopsy study.

Authors:  Hugh Kearney; Tucker Price; Jane Cryan; Alan Beausang; Seamus Looby; Francesca M Brett; Michael Farrell
Journal:  Ir J Med Sci       Date:  2019-02-15       Impact factor: 1.568

4.  Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis.

Authors:  Piotr Sowa; Gro Owren Nygaard; Atle Bjørnerud; Elisabeth Gulowsen Celius; Hanne Flinstad Harbo; Mona Kristiansen Beyer
Journal:  Neuroradiology       Date:  2017-06-05       Impact factor: 2.804

5.  >CME/CNE ARTICLE: Severity Grading in Multiple Sclerosis: A Proposal.

Authors:  Robert Charlson; Joshua Herbert; Ilya Kister
Journal:  Int J MS Care       Date:  2016 Sep-Oct

Review 6.  Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis.

Authors:  Anastasie M Dunn-Pirio; Benjamin M Heyman; Dan S Kaufman; Revere P Kinkel
Journal:  Curr Treat Options Neurol       Date:  2019-10-17       Impact factor: 3.598

7.  Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.

Authors:  J Das; J A Snowden; J Burman; M S Freedman; H Atkins; M Bowman; R K Burt; R Saccardi; C Innocenti; S Mistry; P J Laud; H Jessop; B Sharrack
Journal:  Mult Scler       Date:  2021-02-10       Impact factor: 6.312

8.  A study of patients with aggressive multiple sclerosis at disease onset.

Authors:  Ulrike W Kaunzner; Gaurav Kumar; Gulce Askin; Susan A Gauthier; Nancy N Nealon; Timothy Vartanian; Jai S Perumal
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-01       Impact factor: 2.570

Review 9.  Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.

Authors:  Paolo A Muraro; Roland Martin; Giovanni Luigi Mancardi; Richard Nicholas; Maria Pia Sormani; Riccardo Saccardi
Journal:  Nat Rev Neurol       Date:  2017-06-16       Impact factor: 42.937

10.  High-Resolution Diffusion Tensor Spinal Cord MRI Measures as Biomarkers of Disability Progression in a Rodent Model of Progressive Multiple Sclerosis.

Authors:  Francesca Gilli; Xi Chen; Andrew R Pachner; Barjor Gimi
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.